Christopher Moreau, CEO of Algernon Pharmaceuticals Inc. (CSE: AGN | OTCQB: AGNPF | FSE: AGW), discusses the growing market for treating idiopathic pulmonary fibrosis and chronic cough.
Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets
» Subscribe to Market One: http://bit.ly/2CYmf2y
Learn more about Algernon on their website: https://algernonpharmaceuticals.com/
See how your company can reach millions of investors on BNN Bloomberg through the Market One Minute: https://bit.ly/2JcqR8X
Engage with Market One
» Like us on Facebook: https://www.facebook.com/marketonemediagroup/
» Follow us on Twitter: https://twitter.com/MarketOneMedia
» Connect with us on LinkedIn: https://www.linkedin.com/company/market-one-media-group-inc-
» Follow us on Instagram: https://www.instagram.com/marketonemediagroup/
source
powered by Auto Youtube Summarize
